


## CLAIMS:


1. A compound of formula (I):




(I)

wherein

$R^1$  is  $C_1$ - $C_6$  alkyl (optionally substituted with 1, 2 or 3 halo substituents and/or with 1 substituent selected from -S-( $C_1$ - $C_3$  alkyl), -O-( $C_1$ - $C_3$  alkyl) (optionally substituted with 1, 2 or 3 F atoms), -O-( $C_3$ - $C_6$  cycloalkyl), -SO<sub>2</sub>-( $C_1$ - $C_3$  alkyl), -CN, -COO-( $C_1$ - $C_2$  alkyl) and -OH);  $C_2$ - $C_6$  alkenyl;  $(CH_2)_q$ -Ar<sub>2</sub>; or a group of formula (i) or (ii)



(i)



(ii)

$R^2$ ,  $R^3$  and  $R^4$  are each independently selected from hydrogen or  $C_1$ - $C_2$  alkyl;

$R^5$ ,  $R^6$ ,  $R^7$  and  $R^8$  are each independently selected from hydrogen or  $C_1$ - $C_2$  alkyl;

-X- is a bond, -CH<sub>2</sub>-, -CH=CH-, -O-, -S-, or -SO<sub>2</sub>-;

-Y- is a bond, -CH<sub>2</sub>- or -O-;

-Z is hydrogen, -OH or -O-( $C_1$ - $C_3$  alkyl);

p is 0, 1 or 2;

q is 0, 1 or 2;

r is 0 or 1;

s is 0, 1, 2 or 3;

t is 0, 1, 2, 3 or 4;

Ar<sub>1</sub> is selected from:

- (i) a phenyl group or a 5- or 6-membered monocyclic heteroaromatic group each of which is optionally substituted with 1, 2, 3, 4 or 5 substituents

(depending on the number of available substitution positions) each independently selected from halo, cyano, C<sub>1</sub>-C<sub>4</sub>alkyl (optionally substituted with 1, 2 or 3 F atoms), -O-(C<sub>1</sub>-C<sub>4</sub> alkyl) (optionally substituted with 1, 2 or 3 F atoms) and -S-(C<sub>1</sub>-C<sub>4</sub> alkyl) (optionally substituted with 1, 2 or 3 F atoms) and/or with 1 substituent selected from pyridinyl, pyrazolyl, phenyl (optionally substituted with 1, 2 or 3 halo substituents), benzyl (optionally substituted with 1, 2 or 3 halo substituents) and phenoxy (optionally substituted with 1, 2 or 3 halo substituents) with the proviso that only C<sub>1</sub>-C<sub>4</sub>alkyl may be a substituent for the H of any -NH- moiety present within a 5- or 6-membered monocyclic heteroaromatic group; or

- (ii) a naphthyl group or an 8-, 9- or 10-membered bicyclic heteroaromatic group each of which is optionally substituted with 1, 2, 3, 4, 5 or 6 substituents (depending on the number of available substitution positions) each independently selected from halo, cyano, C<sub>1</sub>-C<sub>4</sub>alkyl (optionally substituted with 1, 2 or 3 F atoms), -O-(C<sub>1</sub>-C<sub>4</sub> alkyl) (optionally substituted with 1, 2 or 3 F atoms) and -S-(C<sub>1</sub>-C<sub>4</sub> alkyl) (optionally substituted with 1, 2 or 3 F atoms) with the proviso that only C<sub>1</sub>-C<sub>4</sub>alkyl may be a substituent for the H of any -NH- moiety present within an 8-, 9- or 10-membered bicyclic heteroaromatic group; and

Ar<sub>2</sub> is selected from

- (i) a phenyl group or a 5- or 6-membered monocyclic heteroaromatic group each of which is optionally substituted with 1, 2, 3, 4 or 5 substituents (depending on the number of available substitution positions) each independently selected from halo, cyano, C<sub>1</sub>-C<sub>4</sub>alkyl (optionally substituted with 1, 2 or 3 F atoms), -O-(C<sub>1</sub>-C<sub>4</sub> alkyl) (optionally substituted with 1, 2 or 3 F atoms) and -S-(C<sub>1</sub>-C<sub>4</sub> alkyl) (optionally substituted with 1, 2 or 3 F atoms) with the proviso that only C<sub>1</sub>-C<sub>4</sub>alkyl may be a substituent for the H of any -NH- moiety present within a 5- or 6-membered monocyclic heteroaromatic group; or

(ii) a naphthyl group or an 8-, 9- or 10-membered bicyclic heteroaromatic group each of which is optionally substituted with 1, 2, 3, 4, 5 or 6 substituents (depending on the number of available substitution positions) each independently selected from halo, cyano, C<sub>1</sub>-C<sub>4</sub>alkyl (optionally substituted with 1, 2 or 3 F atoms), -O-(C<sub>1</sub>-C<sub>4</sub> alkyl) (optionally substituted with 1, 2 or 3 F atoms) and -S-(C<sub>1</sub>-C<sub>4</sub> alkyl) (optionally substituted with 1, 2 or 3 F atoms) with the proviso that only C<sub>1</sub>-C<sub>4</sub>alkyl may be a substituent for the H of any -NH- moiety present within an 8-, 9- or 10-membered bicyclic heteroaromatic group;

or a pharmaceutically acceptable salt thereof; provided that:

(a) the cyclic portion of the group of formula (i) must contain at least three carbon atoms and not more than seven ring atoms;

(b) when -X- is -CH=CH-, then the cyclic portion of the group of formula (i) must contain at least five carbon atoms;

(c) when -Z is -OH or -O-(C<sub>1</sub>-C<sub>3</sub> alkyl), then -X- is -CH<sub>2</sub>-;

(d) when -Y- is -O- then p cannot be 0; and

(e) the compound 3-[(phenylmethyl)-(3S)-3-pyrrolidinylamino]-propanenitrile is excluded.

2. A compound according to claim 1 wherein

Ar<sub>1</sub> is phenyl, pyridinyl, thiazolyl, benzothiophenyl or naphthyl; wherein said phenyl, pyridinyl or thiazolyl group may be substituted with 1, 2 or 3 substituents each independently selected from halo, cyano, C<sub>1</sub>-C<sub>4</sub> alkyl (optionally substituted with 1, 2 or 3 F atoms), -O-(C<sub>1</sub>-C<sub>4</sub> alkyl) (optionally substituted with 1, 2 or 3 F atoms) and -S-(C<sub>1</sub>-C<sub>4</sub> alkyl) (optionally substituted with 1, 2 or 3 F atoms) and/or with 1 substituent selected from pyridinyl, pyrazolyl, phenyl (optionally substituted with 1, 2 or 3 halo substituents) and phenoxy (optionally substituted with 1, 2 or 3 halo substituents); and wherein said benzothiophenyl or naphthyl group may be optionally substituted with 1, 2 or 3 substituents each independently selected from halo, cyano, C<sub>1</sub>-C<sub>4</sub> alkyl (optionally substituted with 1, 2 or 3 F


atoms), -O-(C<sub>1</sub>-C<sub>4</sub> alkyl) (optionally substituted with 1, 2 or 3 F atoms), and -S-(C<sub>1</sub>-C<sub>4</sub> alkyl) (optionally substituted with 1, 2 or 3 F atoms); and

Ar<sub>2</sub> is naphthyl, pyridinyl, thiazolyl, furanyl, thiophenyl, benzothiophenyl, or phenyl, wherein said naphthyl, pyridinyl, thiazolyl, furanyl, thiophenyl,


benzothiophenyl, or phenyl may be substituted with 1, 2 or 3 substituents each independently selected from halo, C<sub>1</sub>-C<sub>4</sub> alkyl (optionally substituted with 1, 2 or 3 F atoms) and -O-(C<sub>1</sub>-C<sub>4</sub> alkyl) (optionally substituted with 1, 2 or 3 F atoms).

3. A compound according to claim 1 or claim 2 wherein


R<sup>1</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, -(CH<sub>2</sub>)<sub>m</sub>-CF<sub>3</sub>, -(CH<sub>2</sub>)<sub>n</sub>-S-(C<sub>1</sub>-C<sub>3</sub> alkyl), -CH<sub>2</sub>-COO-(C<sub>1</sub>-C<sub>2</sub> alkyl), -(C<sub>1</sub>-C<sub>5</sub> alkylene)-O-(C<sub>1</sub>-C<sub>3</sub> alkyl), -(C<sub>1</sub>-C<sub>5</sub> alkylene)-O-(C<sub>3</sub>-C<sub>6</sub> cycloalkyl), -(C<sub>1</sub>-C<sub>5</sub> alkylene)-SO<sub>2</sub>-(C<sub>1</sub>-C<sub>3</sub> alkyl), -(C<sub>1</sub>-C<sub>5</sub> alkylene)-OCF<sub>3</sub>, -(C<sub>1</sub>-C<sub>6</sub> alkylene)-OH, -(C<sub>1</sub>-C<sub>5</sub> alkylene)-CN, -(CH<sub>2</sub>)<sub>q</sub>-Ar<sub>2</sub> or a group of formula (ia), (ib) or (ii)



(ia)



(ib)



(ii)

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, -X-, -Y-, p, q, r and s are as defined in claim 1;

m is 1, 2 or 3;

n is 1, 2 or 3;

t is 2, 3 or 4;

-Ar<sub>1</sub> is phenyl, pyridinyl, thiazolyl or naphthyl; wherein said phenyl, pyridinyl or thiazolyl group may be substituted with 1, 2 or 3 substituents each independently selected from halo, trifluoromethyl, cyano, C<sub>1</sub>-C<sub>4</sub> alkyl, -O-(C<sub>1</sub>-C<sub>4</sub> alkyl), -O-(C<sub>1</sub>-C<sub>4</sub> difluoroalkyl), -O-(C<sub>1</sub>-C<sub>4</sub> trifluoroalkyl), -S-(C<sub>1</sub>-C<sub>4</sub> alkyl), -S-(C<sub>1</sub>-C<sub>2</sub>

trifluoroalkyl) and/or with 1 substituent selected from pyridinyl, pyrazolyl, phenyl (optionally substituted with 1, 2 or 3 halo substituents) and phenoxy (optionally substituted with 1, 2 or 3 halo substituents); and wherein said naphthyl group may

be optionally substituted with 1, 2 or 3 substituents each independently selected from halo, trifluoromethyl, cyano, C<sub>1</sub>-C<sub>4</sub> alkyl, -O-(C<sub>1</sub>-C<sub>4</sub> alkyl), -O-(C<sub>1</sub>-C<sub>4</sub> difluoroalkyl), -O-(C<sub>1</sub>-C<sub>4</sub> trifluoroalkyl), -S-(C<sub>1</sub>-C<sub>4</sub> alkyl), -S-(C<sub>1</sub>-C<sub>2</sub> trifluoroalkyl);

5 Ar<sub>2</sub> is naphthyl, pyridinyl, thiazolyl, furanyl, thiophenyl, benzothiophenyl, or phenyl, wherein said naphthyl, pyridinyl, thiazolyl, furanyl, thiophenyl, benzothiophenyl, or phenyl may be substituted with 1, 2 or 3 substituents each independently selected from halo, C<sub>1</sub>-C<sub>4</sub> alkyl, trifluoromethyl and -O-(C<sub>1</sub>-C<sub>4</sub> alkyl).

10

4. A compound according to any one of claims 1 to 3 wherein R<sup>2</sup> is hydrogen.
5. A compound according to any one of claims 1 to 4 wherein R<sup>3</sup> and R<sup>4</sup> are hydrogen.
- 15 6. A compound according to any one of claims 1 to 5 wherein each R<sup>5</sup> and R<sup>6</sup> is hydrogen.
7. A compound according to any one of claims 1 to 6 wherein each R<sup>7</sup> and R<sup>8</sup> is hydrogen.
- 20 8. A compound according to any one of claims 1 to 5 wherein R<sup>1</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl.
9. A compound according to any one of claims 1 to 5 wherein R<sup>1</sup> is propyl.
- 25 10. A compound according to any one of claims 1 to 5 wherein R<sup>1</sup> is -(C<sub>4</sub>-C<sub>5</sub> alkylene)-OH.
11. A compound according to any one of claims 1 to 7 wherein R<sup>1</sup> is a group of  
30 formula (i), r is 0, s is 2, t is 2, -Z is hydrogen and -X- is -O-, -S- or -SO<sub>2</sub>-.

12. A compound according to any one of claims 1 to 7 wherein R<sup>1</sup> is tetrahydro-2H-pyran-4-yl.
13. A compound according to any one of claims 1 to 7 wherein R<sup>1</sup> is a group of  
5 formula (i), r is 0, s is 1, 2 or 3, t is 1, -Z is hydrogen and -X- is -CH<sub>2</sub>-.
14. A compound according to any one of claims 1 to 7 wherein R<sup>1</sup> is a group of formula (i), r is 1, s is 0, 1, 2 or 3, t is 1, -Z is hydrogen and -X- is -CH<sub>2</sub>-.
- 10 15. A compound according to any one of claims 3 to 7 wherein R<sup>1</sup> is a group of the formula (ib), r is 1, t is 3, and each R<sup>7</sup> and R<sup>8</sup> is hydrogen.
16. A compound according to any one of claims 1 to 7 wherein R<sup>1</sup> is -(CH<sub>2</sub>)<sub>q</sub>-Ar<sub>2</sub>, and  
15 q is 1.
17. A compound according to claim 16 wherein -Ar<sub>2</sub> is pyridinyl, phenyl or phenyl substituted with 1, 2 or 3 substituents each independently selected from halo, trifluoromethyl or C<sub>1</sub>-C<sub>4</sub> alkyl.
- 20 18. A compound according to any one of claims 1 to 17 wherein -Ar<sub>1</sub> is phenyl; phenyl substituted with 1, 2 or 3 substituents each independently selected from halo, trifluoromethyl and C<sub>1</sub>-C<sub>4</sub> alkyl and/or with 1 substituent selected from phenyl, phenyl substituted with 1, 2 or 3 halo substituents, pyridinyl, pyrazolyl, phenoxy and phenoxy substituted with 1, 2 or 3 halo substituents; pyridinyl; or  
25 pyridinyl substituted with 1, 2 or 3 substituents each independently selected from halo, trifluoromethyl and C<sub>1</sub>-C<sub>4</sub> alkyl and/or with 1 substituent selected from phenyl and phenyl substituted with 1, 2 or 3 halo substituents.
- 30 19. A compound according to any one of claims 1 to 18 wherein -Ar<sub>1</sub> is phenyl or phenyl substituted with 1, 2 or 3 substituents each independently selected from halo, trifluoromethyl and C<sub>1</sub>-C<sub>4</sub> alkyl and/or with 1 substituent selected from phenyl, phenyl substituted with 1, 2 or 3 halo substituents, pyridinyl, pyrazolyl,

phenoxy and phenoxy substituted with 1, 2 or 3 halo substituents.

20. A compound according to any one of claims 1 to 19 wherein  $-Ar_1$  is phenyl substituted with 1 or 2 substituents each independently selected from halo, trifluoromethyl and  $C_1$ - $C_4$  alkyl and/or with 1 substituent selected from phenyl, phenyl substituted with 1, 2 or 3 halo substituents, pyridinyl, pyrazolyl, phenoxy and phenoxy substituted with 1, 2 or 3 halo substituents.
21. A compound according to any one of claims 1 to 20 wherein  $-Ar_1$  is phenyl substituted with a trifluoromethyl substituent at the 2-position and optionally substituted with a fluoro substituent at the 5-position.
22. A compound according to any one of claims 1 to 18 wherein  $-Ar_1$  is pyridinyl or pyridinyl substituted with 1, 2 or 3 substituents each independently selected from halo, trifluoromethyl and  $C_1$ - $C_4$  alkyl and/or with 1 substituent selected from phenyl and phenyl substituted with 1, 2 or 3 halo substituents.
23. A compound according to any one of claims 1 to 18 wherein  $-Ar_1$  is pyridinyl substituted with 1 or 2 substituents each independently selected from halo, trifluoromethyl and  $C_1$ - $C_4$  alkyl and/or with 1 substituent selected from phenyl and phenyl substituted with 1, 2 or 3 halo substituents.
24. A pharmaceutical composition comprising a compound as claimed in any one of claims 1 to 23 or a pharmaceutically acceptable salt thereof or 3-[(phenylmethyl)-(3S)-3-pyrrolidinylamino]-propanenitrile or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable diluent or carrier.
25. A compound as claimed in any one of claims 1 to 23 or a pharmaceutically acceptable salt thereof or 3-[(phenylmethyl)-(3S)-3-pyrrolidinylamino]-propanenitrile or a pharmaceutically acceptable salt thereof, for use in therapy.

26. Use of a compound as claimed in any one of claims 1 to 23 or a pharmaceutically acceptable salt thereof or 3-[(phenylmethyl)-(3S)-3-pyrrolidinylamino]-propanenitrile or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating a disorder of the nervous system.
- 5
27. A method for inhibiting the uptake of one or more monoamines selected from serotonin, dopamine and norepinephrine in a mammal, comprising administering to a mammal in need of such inhibition an effective amount of a compound as claimed in any one of Claims 1 to 23 or a pharmaceutically acceptable salt thereof or 3-[(phenylmethyl)-(3S)-3-pyrrolidinylamino]-propanenitrile or a pharmaceutically acceptable salt thereof.
- 10
28. A method for treating disorders associated with dysfunction of the uptake of one or more monoamines selected from serotonin, dopamine and norepinephrine in a mammal, comprising administering to a patient in need thereof an effective amount of a compound as claimed in any one of claims 1 to 23 or a pharmaceutically acceptable salt thereof or 3-[(phenylmethyl)-(3S)-3-pyrrolidinylamino]-propanenitrile or a pharmaceutically acceptable salt thereof.
- 15
29. A method for treating a disorder selected from the group consisting of addictive disorder and withdrawal syndrome, an adjustment disorder (including depressed mood, anxiety, mixed anxiety and depressed mood, disturbance of conduct, and mixed disturbance of conduct and mood), an age-associated learning and mental disorder (including Alzheimer's disease), alcohol addiction, anorexia nervosa, apathy, an attention-deficit disorder (ADD) due to general medical conditions, attention-deficit hyperactivity disorder (ADHD) including the predominantly inattentive type of ADHD and the predominantly hyperactive-impulsive type of ADHD, bipolar disorder, bulimia nervosa, chronic fatigue syndrome, chronic or acute stress, cognitive disorders (including mild cognitive impairment (MCI) and cognitive impairment associated with schizophrenia (CIAS)), communication disorders (including stuttering, expressive language disorder, mixed receptive-expressive language disorder, phonological disorder and communication disorder
- 20
- 25
- 30



not otherwise specified), conduct disorder, cyclothymic disorder, dementia of the  
Alzheimers type (DAT), depression (including adolescent depression and minor  
depression), dysthymic disorder, emotional dysregulation (including emotional  
dysregulation associated with ADHD, borderline personality disorder, bipolar  
5 disorder, schizophrenia, schizoaffective disorder and intermittent explosive  
disorder), fibromyalgia and other somatoform disorders (including somatization  
disorder, conversion disorder, pain disorder, hypochondriasis, body dysmorphic  
disorder, undifferentiated somatoform disorder, and somatoform NOS),  
generalized anxiety disorder (GAD), hot flashes or vasomotor symptoms,  
10 hypotensive states including orthostatic hypotension, impulse control disorders  
(including intermittent explosive disorder, kleptomania, pyromania, pathological  
gambling, trichotillomania and impulse-control disorder not otherwise specified),  
incontinence (i.e., stress incontinence, genuine stress incontinence, and mixed  
incontinence), an inhalation disorder, an intoxication disorder, learning disabilities  
15 (including developmental speech and language disorders (such as developmental  
articulation disorder, developmental expressive language disorder and  
developmental receptive language disorder), learning disorders (such as reading  
disorder, mathematics disorder, disorder of written expression and learning  
disorder not otherwise specified) and motor skills disorders (such as  
20 developmental coordination disorder)), mania, migraine headaches, nicotine  
addiction, obesity (i.e., reducing the weight of obese or overweight patients),  
obsessive compulsive disorders and related spectrum disorders, oppositional  
defiant disorder, pain including chronic pain, neuropathic pain and antinociceptive  
pain, panic disorder, peripheral neuropathy, post-traumatic stress disorder,  
25 personality change due to a general medical condition (including labile type,  
disinhibited type, aggressive type, apathetic type, paranoid type, combined type  
and unspecified type), pervasive developmental disorders (including autistic  
disorder, Asperger's disorder, Rett's disorder, childhood disintegrative disorder,  
and pervasive developmental disorder not otherwise specified), premenstrual  
30 dysphoric disorder (i.e., premenstrual syndrome and late luteal phase dysphoric  
disorder), psoriasis, a psychoactive substance use disorder, a psychotic disorder  
(including schizophrenia, schizoaffective and schizophreniform disorders),

seasonal affective disorder, selective serotonin reuptake inhibition (SSRI) "poop out" syndrome (i.e., wherein a patient who fails to maintain a satisfactory response to SSRI therapy after an initial period of satisfactory response), a sleep disorder (such as narcolepsy and enuresis), social phobia (including social anxiety disorder), a specific developmental disorder, TIC disorders (e.g., Tourette's Disease), tobacco addiction and vascular dementia, comprising administering to a patient in need thereof an effective amount of a compound as claimed in any one of claims 1 to 23 which selectively inhibits the reuptake of norepinephrine over serotonin and dopamine or a pharmaceutically acceptable salt thereof.

30. A method as claimed in claim 29 wherein the disorder is ADHD.

31. A method as claimed in claim 29 wherein the disorder is a cognitive disorder.

32. A method for treating a patient suffering from or susceptible to psychosis, comprising administering to said patient an effective amount of a first component which is an antipsychotic, in combination with an effective amount of a second component which is a compound as claimed in any one of claims 1 to 23 that selectively inhibits the reuptake of norepinephrine over serotonin and dopamine.

33. A pharmaceutical composition which comprises a first component that is an antipsychotic, and a second component that is a compound as claimed in any one of claims 1 to 23 that selectively inhibits the reuptake of norepinephrine over serotonin and dopamine.

34. A method for treating a disorder selected from the group consisting of depression, eating disorders (including bulimia and anorexia nervosa), inflammatory bowel disorders, functional bowel disorders, dyspepsia, Crohn's disease, ileitis, ischemic bowel disease, ulcerative colitis, gastroesophageal reflux for functional bowel disorders, irritable bowel syndrome, obesity, interstitial cystitis, urethral syndrome, gastric motility disorders, substance abuse (including alcoholism, tobacco abuse, symptoms caused by withdrawal or partial withdrawal from the use

of tobacco or nicotine and drug addiction including cocaine abuse), pain (including inflammatory pain, neuropathic pain, non-neuropathic non-inflammatory pain, persistent pain, persistent pain of inflammatory and/or neuropathic origin, headache and migraine), incontinence (including stress urinary incontinence and urge incontinence), dementia of ageing, senile dementia, Alzheimer's, memory loss, Parkinsonism, attention-deficit disorder (including attention-deficit hyperactivity disorder), anxiety, social phobia, disruptive behavior disorders, impulsive control disorders, borderline personality disorder, chronic fatigue syndrome, panic disorders, obsessive compulsive disorder, post-traumatic stress disorder, schizophrenia, gastrointestinal disorders, cardiovascular disorders, hot flushes/flushes emesis, sleep disorders, cognitive disorders, psychotic disorders, brain trauma, premenstrual syndrome or late luteal syndrome, sexual dysfunction (including premature ejaculation and erectile difficulty), autism, mutism and trichotilomania, comprising administering to a patient in need thereof an effective amount of a compound as claimed in any one of claims 1 to 23 which selectively inhibits the reuptake of norepinephrine and serotonin over dopamine or a pharmaceutically acceptable salt thereof.

35. A method for treating a disorder selected from the group consisting of depression, obesity, compulsive disorders (including bulimia, obsessive compulsive disorder, drug addiction including cocaine abuse and alcohol addiction), hypertension, senile dementia, Alzheimer's, memory loss, attention-deficit hyperactivity disorder (ADHD), sexual dysfunction, Parkinsonism, anxiety, chronic fatigue syndrome, panic disorders, cognitive disorders, schizophrenia, gastrointestinal disorders, headache, cardiovascular disorders, epilepsy, smoking cessation, pain including chronic pain, urinary incontinence, emesis and sleep disorders, comprising administering to a patient in need thereof an effective amount of a compound as claimed in any one of claims 1 to 23 which inhibits the reuptake of norepinephrine, serotonin and dopamine or a pharmaceutically acceptable salt thereof.

36. A method for treating ADHD, cognitive disorders, depression, obesity or schizophrenia comprising administering to a patient in need thereof an effective amount of a compound selected from the group consisting of
- (3*S*)-*N*-(1-Methylethyl)-*N*-{[3,5-dichlorophenyl]-methyl}pyrrolidin-3-amine,  
5 (3*S*)-*N*-(1-Methylethyl)-*N*-{[2-(methylthio)phenyl]methyl}-pyrrolidin-3-amine,  
(3*S*)-*N*-(1-Methylethyl)-*N*-{[2-(trifluoromethyl)oxy]-phenyl}methylpyrrolidin-3-amine,  
(3*S*)-*N*-[(3,5-Dimethylphenyl)methyl]-*N*-(1-methylethyl)-pyrrolidin-3-amine,  
(3*S*)-*N*-[(3-Chlorophenyl)methyl]-*N*-(1-methylethyl)-pyrrolidin-3-amine,  
10 (3*S*)-*N*-[(2,3-Dichlorophenyl)methyl]-*N*-(1-methylethyl)-pyrrolidin-3-amine,  
(3*S*)-*N*-[(2,3-Dimethylphenyl)methyl]-*N*-(1-methylethyl)-pyrrolidin-3-amine,  
(3*S*)-*N*-[(2,4-Dichlorophenyl)methyl]-*N*-(1-methylethyl)-pyrrolidin-3-amine,  
(3*S*)-*N*-(Cyclohexylmethyl)-*N*-[(2-methylphenyl)methyl]-pyrrolidin-3-amine,  
(3*S*)-*N*-(Cyclohexylmethyl)-*N*-{[2-(methylthio)phenyl]-methyl}pyrrolidin-3-amine,  
15 (3*S*)-*N*-(Cyclohexylmethyl)-*N*-[(2-fluorophenyl)methyl]-pyrrolidin-3-amine,  
(3*S*)-*N*-(Cyclohexylmethyl)-*N*-(naphthalene-1-ylmethyl)-pyrrolidin-3-amine,  
(3*S*)-*N*-[(2-Chlorophenyl)methyl]-*N*-(cyclohexylmethyl)-pyrrolidin-3-amine,  
(3*S*)-*N*-(Cyclohexylmethyl)-*N*-({2-[1-(methylethyl)oxy]-phenyl}methyl)pyrrolidin-3-amine,  
20 (3*S*)-*N*-Cyclopentyl-*N*-[(2,4-dichlorophenyl)methyl]-pyrrolidin-3-amine,  
(3*S*)-*N*-Cyclopentyl-*N*-{[2-(trifluoromethyl)phenyl]methyl}-pyrrolidin-3-amine,  
(3*S*)-*N*-Cyclopentyl-*N*-[(3-chlorophenyl)methyl]-pyrrolidin-3-amine,  
(3*S*)-*N*-Cyclopentyl-*N*-[(2-chlorophenyl)methyl]-pyrrolidin-3-amine,  
25 (3*S*)-*N*-Cyclopentyl-*N*-{[4-(trifluoromethyl)phenyl]methyl}-pyrrolidin-3-amine,  
(3*S*)-*N*-Cyclopentyl-*N*-{[2-(methylthio)phenyl]methyl}-pyrrolidin-3-amine,  
(3*S*)-*N*-Cyclopentyl-*N*-{[3-(trifluoromethyl)phenyl]methyl}-pyrrolidin-3-amine,  
(3*S*)-*N*-Cyclopentyl-*N*-{[5-fluoro-2-(trifluoromethyl)-phenyl]methyl}-pyrrolidin-3-amine,  
30 (3*S*)-*N*-Cyclopentyl-*N*-{[2-(difluoromethoxy)phenyl]methyl}-pyrrolidin-3-amine,  
(3*S*)-*N*-Cyclopentyl-*N*-{[5-fluoro-2-(trifluoromethyl)-phenyl]methyl}-pyrrolidin-3-amine,

---

(3*S*)-*N*-Cyclopentyl-*N*-[(2,4-dimethylphenyl)methyl]-pyrrolidin-3-amine,  
(3*S*)-*N*-Cyclopentyl-*N*-[(3,5-dimethylphenyl)methyl]-pyrrolidin-3-amine,  
(3*S*)-*N*-Cyclopentyl-*N*-[(2,5-dimethylphenyl)methyl]-pyrrolidin-3-amine,  
(3*S*)-*N*-Cyclopentyl-*N*-[(2,4-difluorophenyl)methyl]-pyrrolidin-3-amine,  
5 (3*S*)-*N*-Cyclopentyl-*N*-{[5-fluoro-3-(trifluoromethyl)-phenyl]methyl}-pyrrolidin-3-amine,

(3*S*)-*N*-Cyclopentyl-*N*-[(3-methylphenyl)methyl]-pyrrolidin-3-amine,  
(3*S*)-*N*-Cyclopentyl-*N*-[(2,3-dimethylphenyl)methyl]-pyrrolidin-3-amine,  
(3*S*)-*N*-Cyclopentyl-*N*-[(2,3-dichlorophenyl)methyl]-pyrrolidin-3-amine,  
10 (3*S*)-*N*-Cyclopentyl-*N*-[(2-chloro-6-fluorophenyl)methyl]-pyrrolidin-3-amine,  
(3*S*)-*N*-Cyclopentyl-*N*-[(3,5-difluorophenyl)methyl]-pyrrolidin-3-amine,  
(3*S*)-*N*-Cyclopentyl-*N*-[(3,5-dichlorophenyl)methyl]-pyrrolidin-3-amine,  
(3*S*)-*N*-Cyclopentyl-*N*-{[2-chloro-3-(trifluoromethyl)-phenyl]methyl}-pyrrolidin-3-amine,

15 (3*S*)-*N*-[2-Chlorophenyl]methyl]-*N*-propylpyrrolidin-3-amine,  
(3*S*)-*N*-Propyl-*N*-{[2-(trifluoromethyl)phenyl]methyl}-pyrrolidin-3-amine,  
(3*S*)-*N*-{5-Fluoro-2-(trifluoromethyl)phenyl]methyl}-*N*-propylpyrrolidin-3-amine,  
(3*S*)-*N*-Cyclobutyl-*N*-{[5-fluoro-2-(trifluoromethyl)-phenyl]methyl}-pyrrolidin-3-amine,

20 (3*S*)-*N*-Cyclobutyl-*N*-[(2,3-dichlorophenyl)methyl]-pyrrolidin-3-amine,  
(3*S*)-*N*-Cyclohexyl-*N*-[(3-methylphenyl)methyl]-pyrrolidin-3-amine,  
(3*S*)-*N*-Cyclohexyl-*N*-{[2-(methylthio)phenyl]methyl}-pyrrolidin-3-amine,  
(3*S*)-*N*-Cyclohexyl-*N*-{[2-(trifluoromethyl)phenyl]methyl}-pyrrolidin-3-amine,  
(3*S*)-*N*-Cyclohexyl-*N*-{[3-(trifluoromethylthio)phenyl]methyl}-pyrrolidin-3-amine,  
25 amine,

(3*S*)-*N*-Cyclohexyl-*N*-[(2,4-dichlorophenyl)methyl]-pyrrolidin-3-amine,  
(3*S*)-*N*-Cyclohexyl-*N*-[(3,5-dichlorophenyl)methyl]-pyrrolidin-3-amine,  
(3*S*)-*N*-Cyclohexyl-*N*-[(2,3-dichlorophenyl)methyl]-pyrrolidin-3-amine,  
(3*S*)-*N*-[(2,4-Dichlorophenyl)methyl]-*N*-(2-methoxy-1-methylethyl)pyrrolidin-3-amine,  
30 amine,

(3*S*)-*N*-[(2-Chloro-4-fluorophenyl)methyl]-*N*-(2-methoxy-1-methylethyl)pyrrolidin-3-amine,

- (3*S*)-*N*-[(3,5-Dichlorophenyl)methyl]-*N*-(2-methoxy-1-methylethyl)pyrrolidin-3-amine,
- (3*S*)-*N*-[(2,3-Dichlorophenyl)methyl]-*N*-(2-methylpropyl)-pyrrolidin-3-amine,
- (3*S*)-*N*-{[2-Chloro-4-fluorophenyl]methyl}-*N*-(1-methylethyl)pyrrolidin-3-amine,
- 5 (3*S*)-*N*-{[4-Fluoro-2-(trifluoromethyl)phenyl]methyl}-*N*-(1-methylethyl)-pyrrolidin-3-amine,
- (3*S*)-*N*-{[2-Fluoro-4-(trifluoromethyl)phenyl]methyl}-*N*-(1-methylethyl)-pyrrolidin-3-amine,
- (3*S*)-*N*-[(3,4-Dichlorophenyl)methyl]-*N*-(1-methylethyl)-pyrrolidin-3-amine,
- 10 (3*S*)-*N*-[(3,5-Dichlorophenyl)methyl]-*N*-(1-methylethyl)-pyrrolidin-3-amine,
- (3*S*)-*N*-[(4-Chlorophenyl)methyl]-*N*-(1-methylethyl)-pyrrolidin-3-amine,
- (3*S*)-*N*-[(3-Methoxyphenyl)methyl]-*N*-(1-methylethyl)-pyrrolidin-3-amine,
- (3*S*)-*N*-[(3-Cyano-4-fluorophenyl)methyl]-*N*-(1-methylethyl)-pyrrolidin-3-amine,
- (3*S*)-*N*-[(2,3-Dimethylphenyl)methyl]-*N*-(1-methylethyl)-pyrrolidin-3-amine,
- 15 (3*S*)-*N*-{[(2-Chloro-3-(trifluoromethyl)phenyl]methyl}-*N*-(1-methylethyl)-pyrrolidin-3-amine,
- (3*S*)-*N*-[(2-Chloro-6-fluorophenyl)methyl]-*N*-(1-methylethyl)-pyrrolidin-3-amine,
- (3*S*)-*N*-[(2,4-Chlorophenyl)methyl]-*N*-(1-methylethyl)-pyrrolidin-3-amine,
- (3*S*)-*N*-{[2-(4-Fluorophenoxy)phenyl]methyl}-*N*-(1-methylethyl)-pyrrolidin-3-
- 20 amine,
- (3*S*)-*N*-{[2-(3,4-Difluorophenoxy)phenyl]methyl}-*N*-(1-methylethyl)-pyrrolidin-3-amine,
- (3*S*)-*N*-{[4'-Fluoro-[1,1'-biphenyl]-2-yl]methyl}-*N*-(1-methylethyl)-pyrrolidin-3-amine,
- 25 (3*S*)-*N*-{[4-Fluoro-2-(trifluoromethyl)phenyl]methyl}-*N*-propylpyrrolidin-3-amine,
- (3*S*)-*N*-Butyl-*N*-{[4-fluoro-2-(trifluoromethyl)phenyl]-methyl}pyrrolidin-3-amine,
- (3*S*)-*N*-Cyclopropylmethyl-*N*-{[4-fluoro-2-(trifluoromethyl)phenyl]-methyl}pyrrolidin-3-amine,
- 30 (3*S*)-*N*-[(3,5-Dichlorophenyl)methyl]-*N*-propylpyrrolidin-3-amine,
- (3*S*)-*N*-Butyl-*N*-[(3,5-dichlorophenyl)methyl]pyrrolidin-3-amine,
- (3*S*)-*N*-Cyclopropylmethyl-*N*-[(3,5-dichlorophenyl)-methyl]pyrrolidin-3-amine,

(3*S*)-*N*-[(2,4-Dichlorophenyl)methyl]-*N*-propylpyrrolidin-3-amine,

(3*S*)-*N*-Butyl-*N*-[(2,4-dichlorophenyl)methyl]pyrrolidin-3-amine,

(3*S*)-*N*-Cyclopropylmethyl-*N*-[(2,4-dichlorophenyl)-methyl]pyrrolidin-3-amine,

(3*S*)-*N*-[(2-Chloro-4-fluorophenyl)methyl]-*N*-propylpyrrolidin-3-amine,

5 (3*S*)-*N*-Butyl-*N*-[(2-chloro-4-fluorophenyl)methyl]-pyrrolidin-3-amine,

(3*S*)- *N*-[(2-Chloro-4-fluorophenyl)methyl]-*N*-(cyclopropylmethyl)pyrrolidin-3-amine,

(3*S*)-*N*-{[4-Fluoro-2-(trifluoromethyl)phenyl]methyl}-*N*-(tetrahydro-2*H*-thiopyran-4-yl)pyrrolidin-3-amine,

10 (3*S*)-*N*-[(2,4-Dichlorophenyl)methyl]-*N*-(tetrahydro-2*H*-thiopyran-4-yl)pyrrolidin-3-amine,

(3*S*)-*N*-[(2,4-Dichlorophenyl)methyl]-*N*-(1,1-dioxido-tetrahydro-2*H*-thiopyran-4-yl)pyrrolidin-3-amine,

15 (3*S*)-*N*-{[5-Fluoro-2-(trifluoromethyl)phenyl]methyl}-*N*-(tetrahydro-2*H*-pyran-4-yl)pyrrolidin-3-amine,

(3*S*)-*N*-{[2-(Trifluoromethyl)phenyl]methyl}-*N*-(tetrahydro-2*H*-pyran-4-yl)pyrrolidin-3-amine,

(3*S*)-*N*-[(2,4-Dichlorophenyl)methyl]-*N*-(tetrahydro-2*H*-pyran-4-yl)pyrrolidin-3-amine,

20 (3*S*)-*N*-[(3,5-Dichlorophenyl)methyl]-*N*-(tetrahydro-2*H*-pyran-4-yl)pyrrolidin-3-amine,

(3*S*)-*N*-[(2-Chloro-4-fluorophenyl)methyl]-*N*-(tetrahydro-2*H*-pyran-4-yl)pyrrolidin-3-amine,

25 (3*S*)-*N*-[(4-Chloro-2-methylphenyl)methyl]-*N*-(tetrahydro-2*H*-pyran-4-yl)pyrrolidin-3-amine,

(3*S*)-*N*-[(2,3-Dichlorophenyl)methyl]-*N*-(tetrahydro-2*H*-pyran-4-yl)pyrrolidin-3-amine,

(3*S*)-*N*-[(2-Chloro-6-fluorophenyl)methyl]-*N*-(tetrahydro-2*H*-pyran-4-yl)pyrrolidin-3-amine,

30 (3*S*)-*N*-{[4-Fluoro-2-(trifluoromethyl)phenyl]methyl}-*N*-(tetrahydro-2*H*-pyran-4-yl)pyrrolidin-3-amine,

(3*S*)-*N*-([1,1'-Biphenyl]-2-ylmethyl)-*N*-(tetrahydro-2*H*-pyran-4-yl)pyrrolidin-3-amine,

(3*S*)-*N*-{(4-Fluoro-[1,1'-biphenyl]-2-yl)methyl}-*N*-(tetrahydro-2*H*-pyran-4-yl)pyrrolidin-3-amine,

5 (3*S*)-*N*-[(2-Chlorophenyl)methyl]-*N*-(tetrahydro-2*H*-pyran-4-yl)pyrrolidin-3-amine,

(3*S*)-*N*-[(2-Chloro-5-fluorophenyl)methyl]-*N*-(tetrahydro-2*H*-pyran-4-yl)pyrrolidin-3-amine,

10 (3*S*)-*N*-[(4-Fluorophenyl)methyl]-*N*-(tetrahydro-2*H*-pyran-4-yl)pyrrolidin-3-amine,

(3*S*)-*N*-{[5-Fluoro-2-(trifluoromethyl)phenyl]methyl}-*N*-(tetrahydro-2*H*-pyran-4-yl)pyrrolidin-3-amine,

(3*S*)-*N*-(1-Methylethyl)-*N*-{[2-(trifluoromethyl)-5-fluorophenyl]methyl}pyrrolidin-3-amine,

15 (3*S*)-*N*-(1-Methylethyl)-*N*-{[3-(trifluoromethyl)phenyl]-methyl}pyrrolidin-3-amine,

(3*S*)-*N*-(1-Methylethyl)-*N*-{[4-(trifluoromethyl)phenyl]-methyl}pyrrolidin-3-amine,

(3*S*)-*N*-([1,1'-Biphenyl]-2-ylmethyl)-*N*-(1-methylethyl)-pyrrolidin-3-amine,

20 (3*S*)-*N*-(1-Methylethyl)-*N*-{[2-phenyloxy]phenyl]methyl}-pyrrolidin-3-amine,

(3*S*)-*N*-(1-Methylethyl)-*N*-{[2-(phenylmethyl)phenyl]-methyl}pyrrolidin-3-amine,

(3*S*)-*N*-{[(2,4-Dichlorophenyl)methyl]-*N*-(2,2,2-trifluoroethyl)amino}pyrrolidin-3-amine,

25 (3*S*)-*N*-{[(3,5-Dichlorophenyl)methyl]-*N*-(2,2,2-trifluoroethyl)amino}pyrrolidin-3-amine,

(3*S*)-*N*-{[2-(Trifluoromethyl)phenyl]methyl}-*N*-(2,2,2-trifluoroethyl)amino]pyrrolidin-3-amine,

(3*S*)-*N*-{[(2,3-Dichlorophenyl)methyl]-*N*-(2,2,2-trifluoroethyl)amino}pyrrolidin-3-amine,

30 (3*S*)-*N*-{[(2-Chloro-3-methylphenyl)methyl]-*N*-(2,2,2-trifluoroethyl)amino}pyrrolidin-3-amine,

Methyl ((3*S*)-pyrrolidin-3-yl{[2-(trifluoromethyl)phenyl]-methyl} amino)acetate,



(3*S*)-*N*-[(2-Chlorophenyl)methyl]-*N*-(2-methylpropyl)-pyrrolidin-3-amine,  
(3*S*)-*N*-{[2-(Methoxy)phenyl]methyl}-*N*-(2-methylpropyl)pyrrolidin-3-amine,  
(3*S*)-*N*-{[2-(Ethyloxy)phenyl]methyl}-*N*-(2-methylpropyl)pyrrolidin-3-amine,  
(3*S*)-*N*-[(2-Methylphenyl)methyl]-*N*-(2-methylpropyl)-pyrrolidin-3-amine,  
5 (3*S*)-*N*-(2-Methylpropyl)-*N*-(phenylmethyl)pyrrolidin-3-amine,  
(3*S*)-*N*-(2-Methylpropyl)-*N*-[(naphthalen-1-yl)methyl]-pyrrolidin-3-amine,  
(3*S*)-*N*-{[4-Fluoro-2-(methoxy)phenyl]methyl}-*N*-(2-methylpropyl)pyrrolidin-3-  
amine,  
(3*S*)-*N*-(2-Methylpropyl)-*N*-{[2-(phenyloxy)phenyl]methyl}-pyrrolidin-3-amine,  
10 (3*S*)-*N*-{[2-Chloro-3-(trifluoromethyl)phenyl]methyl}-*N*-(2-  
methylpropyl)pyrrolidin-3-amine,  
(3*S*)-*N*-[(2-Chloro-4-fluorophenyl)methyl]-*N*-(2-methylpropyl)pyrrolidin-3-  
amine,  
(3*S*)-*N*-[(2,4-Dichlorophenyl)methyl]-*N*-(2-methylpropyl)-pyrrolidin-3-amine,  
15 (3*R*)-*N*-{[2-Chloro-3-(trifluoromethyl)phenyl]methyl}-*N*-(2-  
methylpropyl)pyrrolidin-3-amine,  
(3*R*)-*N*-[(2-Chloro-3-methylphenyl)methyl]-*N*-(2-methylpropyl)pyrrolidin-3-  
amine,  
(3*R*)-*N*-[(2-Chloro-4-fluorophenyl)methyl]-*N*-(2-methylpropyl)pyrrolidin-3-  
20 amine,  
(3*S*)-*N*-{[3-Fluoro-2-(trifluoromethyl)phenyl]methyl}-*N*-(2-  
methylpropyl)pyrrolidin-3-amine,  
(3*R*)-*N*-{[4-Fluoro-2-(trifluoromethyl)phenyl]methyl}-*N*-(2-  
methylpropyl)pyrrolidin-3-amine,  
25 (3*S*)-*N*-(2-Methylpropyl)-*N*-{[2-(methylthio)phenyl]methyl}-pyrrolidin-3-amine,  
(3*R*)-*N*-(2-Methylpropyl)-*N*-{[2-(methylthio)phenyl]methyl}-pyrrolidin-3-amine,  
(3*S*)-*N*-[(2-Chloro-3-methylphenyl)methyl]-*N*-(2-methylpropyl)-pyrrolidin-3-  
amine,  
(3*S*)-*N*-[(3,5-Dichlorophenyl)methyl]-*N*-(2-methylpropyl)-pyrrolidin-3-amine,  
30 (3*S*)-*N*-[(3-Chloro-2-methylphenyl)methyl]-*N*-(2-methylpropyl)-pyrrolidin-3-  
amine,

(3*S*)-*N*-(3,3-Dimethylbutyl)-*N*-{[2-(trifluoromethyl)-phenyl]methyl}pyrrolidin-3-amine,

(3*S*)-*N*-(1-Methylethyl)-*N*-{[2-(trifluoromethyl)-phenyl]methyl}pyrrolidin-3-amine,

5 (3*S*)-*N*-(2-methylpropyl)-*N*-{[2-(trifluoromethyl)phenyl]-methyl}pyrrolidin-3-amine,

(3*R*)-*N*-(2-Methylpropyl)-*N*-{[2-(trifluoromethyl)phenyl]-methyl}pyrrolidin-3-amine,

(3*S*)-*N*-Ethyl-*N*-{[2-(trifluoromethyl)phenyl]methyl}-pyrrolidin-3-amine,

10 (3*S*)-*N*-Propyl-*N*-{[2-(trifluoromethyl)phenyl]methyl}-pyrrolidin-3-amine,

(3*S*)-*N*-(Cyclohexylmethyl)-*N*-{[2-(trifluoromethyl)-phenyl]methyl}pyrrolidin-3-amine,

(3*S*)-*N*-(Cyclopropylmethyl)-*N*-{[2-(trifluoromethyl)-phenyl]methyl}pyrrolidin-3-amine,

15 (3*S*)-*N*-(2-Phenylethyl)-*N*-{[2-(trifluoromethyl)phenyl]-methyl}pyrrolidin-3-amine,

(3*S*)-*N*-Butyl-*N*-{[2-(trifluoromethyl)phenyl]methyl}-pyrrolidin-3-amine,

(3*S*)-*N*-(2-Ethylbutyl)-*N*-{[2-(trifluoromethyl)phenyl]-methyl}pyrrolidin-3-amine,

(3*S*)-*N*-(2-Methylprop-2-enyl)-*N*-{[2-(trifluoromethyl)-phenyl]methyl}pyrrolidin-3-amine,

20 (3*S*)-*N*-{[2-(Trifluoromethyl)phenyl]methyl}-*N*-(3,3,3-trifluoropropyl)pyrrolidin-3-amine,

(3*S*)-*N*-(4,4,4-Trifluorobutyl)-*N*-{[2-(trifluoromethyl)-phenyl]methyl}pyrrolidin-3-amine,

25 (3*S*)-*N*-(Furan-2-ylmethyl)-*N*-{[2-(trifluoromethyl)phenyl]-methyl}pyrrolidin-3-amine,

(3*S*)-*N*-(3-Methylbutyl)-*N*-{[2-(trifluoromethyl)phenyl]-methyl}pyrrolidin-3-amine,

30 (3*S*)-*N*-[3-(Methylthio)propyl]-*N*-{[2-(trifluoromethyl)-phenyl]methyl}pyrrolidin-3-amine,

(3*S*)-*N*-(2,2-Dimethylpropyl)-*N*-{[2-(trifluoromethyl)-phenyl]methyl}pyrrolidin-3-amine,

*N*-(Phenylmethyl)-*N*-[(3*S*)-pyrrolidin-3-yl]-*N*-{[2-(trifluoromethyl)phenyl]methyl}amine,  
(3*S*)-*N*-[(4-Fluorophenyl)methyl]-*N*-{[2-(trifluoromethyl)phenyl]methyl}pyrrolidin-3-amine,  
5 (3*S*)-*N*-{[2-(Ethyloxy)phenyl]methyl}-*N*-{[2-(trifluoromethyl)phenyl]methyl}pyrrolidin-3-amine,  
(3*S*)-*N*-[(2-Chlorophenyl)methyl]-*N*-{[2-(trifluoromethyl)phenyl]methyl}pyrrolidin-3-amine,  
(3*S*)-*N*-[(2-Fluorophenyl)methyl]-*N*-{[2-(trifluoromethyl)phenyl]methyl}pyrrolidin-3-amine,  
10 (3*S*)-*N*-{[2-(Methyloxy)phenyl]methyl}-*N*-{[2-(trifluoromethyl)phenyl]methyl}pyrrolidin-3-amine,  
(3*S*)-*N,N*-bis{[2-(Trifluoromethyl)phenyl]methyl}-pyrrolidin-3-amine,  
(3*S*)-*N*-(2-Ethylbutyl)-*N*-{[2-(trifluoromethyl)phenyl]methyl}pyrrolidin-3-amine,  
15 (3*S*)-*N*-{[2-(Trifluoromethyl)phenyl]methyl}-*N*-(3,3,3-trifluoropropyl)pyrrolidin-3-amine,  
(3*S*)-*N*-(4,4,4-Trifluorobutyl)-*N*-{[2-(trifluoromethyl)phenyl]methyl}pyrrolidin-3-amine,  
(3*S*)-*N*-Ethyl-*N*-{[2-(trifluoromethyl)phenyl]methyl}-pyrrolidin-3-amine,  
20 (3*S*)-*N,N*-bis-[(2-Chloro-4-fluorophenyl)methyl]-pyrrolidin-3-amine,  
(3*S*)-*N,N*-bis-[(2,4-Dichlorophenyl)methyl]-pyrrolidin-3-amine,  
1-{[(3,5-Dichlorophenyl)methyl][(3*S*)-pyrrolidin-3-yl]amino}-2-methylpropan-2-ol,  
1-{[(2,4-Dichlorophenyl)methyl][(3*S*)-pyrrolidin-3-yl]amino}-2-methylpropan-2-ol,  
25 1-{{[4-Fluoro-2-(trifluoromethyl)phenyl]methyl}[(3*S*)-pyrrolidin-3-yl]amino}-2-methylpropan-2-ol,  
1-{[(2-Chloro-4-fluorophenyl)methyl][(3*S*)-pyrrolidin-3-yl]amino}-2-methylpropan-2-ol,  
30 1-{[(2-Chloro-6-fluorophenyl)methyl][(3*S*)-pyrrolidin-3-yl]amino}-2-methylpropan-2-ol,

1-{[(2-Phenyl-5-fluorophenyl)methyl][(3*S*)-pyrrolidin-3-yl]amino}-2-methylpropan-2-ol,

1-{{[2-(Trifluoromethyl)phenyl]methyl}[(3*S*)-pyrrolidin-3-yl]amino}-2-methylpropan-2-ol,

5 *N*-(2-Methylpropyl)-*N*-(4-methylbenzyl)-pyrrolidin-3-amine,

*N*-(2-Methylpropyl)-*N*-(4-chlorobenzyl)-pyrrolidin-3-amine,

*N*-(2-Methylpropyl)-*N*-(4-methoxybenzyl)-pyrrolidin-3-amine,

*N*-(2-Methylpropyl)-*N*-(3,4-dichlorobenzyl)-pyrrolidin-3-amine,

*N*-(2-Methylpropyl)-*N*-(2-trifluoromethylbenzyl)-pyrrolidin-3-amine,

10 *N*-Cyclohexylmethyl-*N*-benzyl-pyrrolidin-3-amine,

*N*-Cyclohexylmethyl-*N*-(4-methoxybenzyl)-pyrrolidin-3-amine,

*N*-Cyclohexylmethyl-*N*-(4-methylbenzyl)-pyrrolidin-3-amine,

*N*-Cyclohexylmethyl-*N*-(3,4-dichlorobenzyl)-pyrrolidin-3-amine,

*N*-Cyclopropylmethyl-*N*-(4-chlorobenzyl)-pyrrolidin-3-amine,

15 *N*-Cyclopropylmethyl-*N*-(4-methoxybenzyl)-pyrrolidin-3-amine,

*N*-Cyclopropylmethyl-*N*-(3,4-dichlorobenzyl)-pyrrolidin-3-amine,

*N*-Cyclopropylmethyl-*N*-(2-trifluoromethylbenzyl)-pyrrolidin-3-amine,

*N*-Butyl-*N*-benzyl-pyrrolidin-3-amine,

*N*-Butyl-*N*-(4-chlorobenzyl)-pyrrolidin-3-amine,

20 *N*-Butyl-*N*-(4-methoxybenzyl)-pyrrolidin-3-amine,

*N*-Butyl-*N*-(4-methylbenzyl)-pyrrolidin-3-amine,

*N*-Butyl-*N*-(3,4-dichlorobenzyl)-pyrrolidin-3-amine,

*N*-Butyl-*N*-(2-trifluoromethylbenzyl)-pyrrolidin-3-amine,

(3*S*)-*N*-[(3*R*)-Tetrahydrofuran-3-yl]-*N*-{[2-

25 (trifluoromethyl)phenyl]methyl}pyrrolidin-3-amine,

(3*S*)-*N*-[(3*S*)-Tetrahydrofuran-3-yl]-*N*-{[2-

(trifluoromethyl)phenyl]methyl}pyrrolidin-3-amine,

(3*S*)-*N*-([1,1'-Biphenyl]-2-ylmethyl)-*N*-[(3*R*)-tetrahydrofuran-3-yl]pyrrolidin-3-amine,

30 (3*S*)-*N*-([1,1'-Biphenyl]-2-ylmethyl)-*N*-[(3*S*)-tetrahydrofuran-3-yl]pyrrolidin-3-amine,

(3*S*)-*N*-[(2-Chloro-6-fluorophenyl)methyl]-*N*-[(3*R*)-tetrahydrofuran-3-yl]pyrrolidin-3-amine,

(3*S*)-*N*-[(2-Chloro-6-fluorophenyl)methyl]-*N*-[(3*S*)-tetrahydrofuran-3-yl]pyrrolidin-3-amine,

5 (3*S*)-*N*-[(Tetrahydrofuran-3-yl)methyl]-*N*-{[2-(trifluoromethyl)phenyl]methyl}pyrrolidin-3-amine,

(3*S*)-*N*-(2-Methylpropyl)-*N*-{[3-phenylpyrid-2-yl]methyl}-pyrrolidin-3-amine,

(3*S*)-*N*-(Cyclohexyl)-*N*-{[2-(3-phenyl)pyridyl]methyl}-pyrrolidin-3-amine,

(3*S*)-*N*-(2-Methylpropyl)-*N*-{[2-(3-pyridyl)-phenyl]methyl}pyrrolidin-3-amine,

10 (3*S*)-*N*-(2-Methylpropyl)-*N*-{[2-(1-pyrazolyl)phenyl]-methyl}pyrrolidine-3-amine,

(3*S*)-*N*-Propyl-*N*-{[2-(trifluoromethyl)phenyl]methyl}-pyrrolidin-3-amine,

(3*S*)-*N*-{5-fluoro-2-(trifluoromethyl)phenyl]methyl}-*N*-propylpyrrolidin-3-amine,

15 (3*S*)-*N*-(Pyridin-3-ylmethyl)-*N*-{[2-(trifluoromethyl)-phenyl]methyl}pyrrolidin-3-amine,

(3*S*)-*N*-[(4-Fluoro[1,1'-biphenyl]-2-methyl)-*N*-(pyridin-2-ylmethyl)pyrrolidin-3-amine,

(3*S*)-*N*-[(4-Fluoro[1,1'-biphenyl]-2-methyl)-*N*-(pyridin-3-ylmethyl)pyrrolidin-3-amine,

20 (3*S*)-*N*-[(2-Chloro-6-fluorophenyl)methyl]-*N*-(pyridin-2-ylmethyl)pyrrolidine-3-amine,

(3*S*)-*N*-[(2-Chloro-6-fluorophenyl)methyl]-*N*-(pyridin-4-ylmethyl)pyrrolidine-3-amine,

25 (3*S*)-*N*-[(2-Chloro-6-fluorophenyl)methyl]-*N*-(pyridin-3-ylmethyl)pyrrolidine-3-amine, and

(3*S*)-*N*-(Pyridin-2-ylmethyl)-*N*-{[2-(trifluoromethyl)-phenyl]methyl}pyrrolidin-3-amine

or a pharmaceutically acceptable salt thereof.